InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,460.48
(
-0.41%
)
US TECH 100
19,191.20
(
-0.38%
)
Dow Jones
39,118.86
(
-0.12%
)
Brent Oil
84.85
(
-0.66%
)
Bitcoin
60,212.08
(
-2.27%
)
Post# of 438
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DanWebzster

Send PM Follow Ignore
Followers 10
Posts 1060
Boards Moderated 2
Alias Born 09/04/2000

DanWebzster

Member Level

Re: DanWebzster post# 176

Monday, 05/28/2018 5:42:21 AM

Monday, May 28, 2018 5:42:21 AM

Post# of 438
NBRV will file an NDA for lemefulin in CABP in Q4/18

Cash runway thru Q1/20

Public float has been bloated to achieve that cash runway

Despite efficacy proven in two Ph3 studies, recent stock weakness has been attributed to safety concerns

Safety concerns focus on diarrhea found in 12% of treatment arm compared to 1% of control arm.

Lemefulin will mostly be prescribed for drug resistant cases of CABP, approximately 5% of the market
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up